Yan AT, et al. - Post-hoc analyses in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial showed a divergence of treatment effect in favor of prasugrel vs clopidogrel after 12 months in patients with non-ST-segment elevation acute coronary syndrome managed medically without revascularization. Consequently, researchers determined the impact of early study drug discontinuation in this exploratory, post-hoc analysis. They analyzed 1,436 patients who received at least one dose of the study drug and discontinued the drug 7–365 days following randomization. Findings of this analysis demonstrated high rates of ischemic events following study drug discontinuation. Patients treated with prasugrel vs clopidogrel had a lower frequency of events that did not persist after multivariable adjustment.